Drug intelligence / Profile preview

PD-H

Development stage: Preclinical
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

PD-H is a specific strain of the oncolytic Coxsackievirus B3 (CVB3) being investigated as a therapeutic agent for various cancers, including pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer. It exerts its anti-tumor activity by robust replication within cancer cells, leading to cell lysis and induction of apoptosis. It has shown potential in enhancing the efficacy of FAK inhibitors in pancreatic cancer and inhibiting tumor growth in syngeneic mouse models.

Other names: Coxsackievirus B3 strain PD-Honcolytic Coxsackievirus B3 strain PD-H

Beyond the preview

Go deeper on PD-H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-H.

Explore the full profile